Status:
COMPLETED
Caffeine Citrate Use and Electronic Activity of the Diaphragm (EDI) Changes
Lead Sponsor:
Seoul St. Mary's Hospital
Conditions:
Preterm
Apnea of Prematurity
Eligibility:
All Genders
Brief Summary
Caffeine citrate, the first-line agent for apnea of prematurity, enhances diaphragmatic activity. EDI values of neurally adjusted ventilatory assist (NAVA) modes can be used to quantify the diaphragma...
Detailed Description
Caffeine citrate has been used as the first-line agent for apnea of prematurity. It works via mechanisms including stimulation of the respiratory center in medulla, increasing sensitivity to carbon di...
Eligibility Criteria
Inclusion
- Preterm infants born at less than 34 weeks' gestation who are supported by invasive or non-invasive NAVA
Exclusion
- major congenital anomaly, chromosomal or genetic abnormality
Key Trial Info
Start Date :
June 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 18 2023
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05393817
Start Date
June 8 2022
End Date
October 18 2023
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul St. Mary's Hospital
Seoul, Seocho-Gu, South Korea, 06591